Guardant Health (GH) Stock Forecast & Price Target

Compare

2,120 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

GH Analyst Ratings

Strong Buy

21 Buy

0 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Guardant

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

GH Stock 12 Month Forecast

Average Price Target

$71.06

▼(-1.51% Downside)

Based on 21 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $71.06 with a high forecast of $90.00 and a low forecast of $60.00. The average price target represents a -1.51% change from the last price of $72.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","56":"$56","91":"$91","38.5":"$38.5","73.5":"$73.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$90.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":71.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$71.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$60.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,38.5,56,73.5,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.65,64.75384615384615,66.8576923076923,68.96153846153845,71.06538461538462,73.16923076923077,75.27307692307693,77.37692307692308,79.48076923076923,81.58461538461538,83.68846153846154,85.79230769230769,87.89615384615385,{"y":90,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.65,63.29692307692308,63.94384615384615,64.59076923076923,65.23769230769231,65.88461538461539,66.53153846153846,67.17846153846153,67.82538461538462,68.4723076923077,69.11923076923077,69.76615384615384,70.41307692307693,{"y":71.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,62.65,62.44615384615385,62.24230769230769,62.03846153846154,61.83461538461538,61.63076923076923,61.426923076923075,61.223076923076924,61.01923076923077,60.815384615384616,60.61153846153846,60.40769230769231,60.20384615384616,{"y":60,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":22.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.47,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.87,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.51,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$90.00

Average Price Target$71.06

Lowest Price Target$60.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

10/27/25

Craig-Hallum Reaffirms Their Buy Rating on Guardant Health (GH)

Kyle Mikson CFA

Canaccord Genuity

$75→$60.07

Buy

-16.74%

Downside

Reiterated

10/27/25

Canaccord Genuity Keeps Their Buy Rating on Guardant Health (GH)

Cira Diagnissa

TR | OpenAI - 4o

$62→$68

Hold

-5.75%

Downside

Reiterated

10/23/25

AI Generated ArticleAI Generated Article

David Westenberg

Piper Sandler

$60→$90

Buy

24.74%

Upside

Reiterated

10/22/25

Guardant Health (GH) Receives a Buy from Piper Sandler

Puneet Souda

Leerink Partners

$75→$85

Buy

17.81%

Upside

Reiterated

10/17/25

Guardant Health (GH) Receives a Buy from Leerink PartnersGH's price target increased from $75.00 to $85.00, confirming our Outperform stance.

Daniel Brennan

TD Cowen

$64.22→$72

Buy

-0.21%

Downside

Reiterated

10/13/25

TD Cowen Keeps Their Buy Rating on Guardant Health (GH)

Daniel Markowitz CFA

Evercore ISI

$60→$68

Buy

-5.75%

Downside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: Illumina (NASDAQ: ILMN) and Guardant Health (NASDAQ: GH)

Luke Sergott

Barclays

$60→$70

Buy

-2.98%

Downside

Reiterated

10/02/25

Guardant Health price target raised to $70 from $60 at BarclaysGuardant Health price target raised to $70 from $60 at Barclays

Tycho Peterson

Jefferies

$60→$75

Buy

3.95%

Upside

Reiterated

09/26/25

Jefferies Remains a Buy on Guardant Health (GH)

Doug Schenkel

Wolfe Research

$75

Buy

3.95%

Upside

Upgraded

09/25/25

Guardant Health upgraded to Outperform from Peer Perform at Wolfe ResearchGuardant Health upgraded to Outperform from Peer Perform at Wolfe Research

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

09/25/25

Guardant Health's Strategic Advancements and Growth Potential Earns Buy Rating

Eve Burstein

Bernstein

$60

Buy

-16.84%

Downside

Reiterated

09/25/25

Bernstein Reaffirms Their Buy Rating on Guardant Health (GH)

Rachel Vatnsdal

J.P. Morgan

$60→$70

Buy

-2.98%

Downside

Reiterated

09/25/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bradley Bowers

Mizuho Securities

$65→$70

Buy

-2.98%

Downside

Reiterated

09/25/25

Guardant Health price target raised to $70 from $65 at MizuhoGuardant Health price target raised to $70 from $65 at Mizuho

Mark Massaro

BTIG

$70→$80

Buy

10.88%

Upside

Reiterated

09/25/25

Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX) and Guardant Health (NASDAQ: GH)we reiterate our Buy rating and $70 PT on GH

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

10/27/25

Craig-Hallum Reaffirms Their Buy Rating on Guardant Health (GH)

Kyle Mikson CFA

Canaccord Genuity

$75→$60.07

Buy

-16.74%

Downside

Reiterated

10/27/25

Canaccord Genuity Keeps Their Buy Rating on Guardant Health (GH)

Cira Diagnissa

TR | OpenAI - 4o

$62→$68

Hold

-5.75%

Downside

Reiterated

10/23/25

AI Generated ArticleAI Generated Article

David Westenberg

Piper Sandler

$60→$90

Buy

24.74%

Upside

Reiterated

10/22/25

Guardant Health (GH) Receives a Buy from Piper Sandler

Puneet Souda

Leerink Partners

$75→$85

Buy

17.81%

Upside

Reiterated

10/17/25

Guardant Health (GH) Receives a Buy from Leerink PartnersGH's price target increased from $75.00 to $85.00, confirming our Outperform stance.

Daniel Brennan

TD Cowen

$64.22→$72

Buy

-0.21%

Downside

Reiterated

10/13/25

TD Cowen Keeps Their Buy Rating on Guardant Health (GH)

Daniel Markowitz CFA

Evercore ISI

$60→$68

Buy

-5.75%

Downside

Reiterated

10/07/25

Analysts Offer Insights on Healthcare Companies: Illumina (NASDAQ: ILMN) and Guardant Health (NASDAQ: GH)

Luke Sergott

Barclays

$60→$70

Buy

-2.98%

Downside

Reiterated

10/02/25

Guardant Health price target raised to $70 from $60 at BarclaysGuardant Health price target raised to $70 from $60 at Barclays

Tycho Peterson

Jefferies

$60→$75

Buy

3.95%

Upside

Reiterated

09/26/25

Jefferies Remains a Buy on Guardant Health (GH)

Doug Schenkel

Wolfe Research

$75

Buy

3.95%

Upside

Upgraded

09/25/25

Guardant Health upgraded to Outperform from Peer Perform at Wolfe ResearchGuardant Health upgraded to Outperform from Peer Perform at Wolfe Research

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

09/25/25

Guardant Health's Strategic Advancements and Growth Potential Earns Buy Rating

Eve Burstein

Bernstein

$60

Buy

-16.84%

Downside

Reiterated

09/25/25

Bernstein Reaffirms Their Buy Rating on Guardant Health (GH)

Rachel Vatnsdal

J.P. Morgan

$60→$70

Buy

-2.98%

Downside

Reiterated

09/25/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Bradley Bowers

Mizuho Securities

$65→$70

Buy

-2.98%

Downside

Reiterated

09/25/25

Guardant Health price target raised to $70 from $65 at MizuhoGuardant Health price target raised to $70 from $65 at Mizuho

Mark Massaro

BTIG

$70→$80

Buy

10.88%

Upside

Reiterated

09/25/25

Analysts Offer Insights on Healthcare Companies: Cidara Therapeutics (NASDAQ: CDTX) and Guardant Health (NASDAQ: GH)we reiterate our Buy rating and $70 PT on GH

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

1 Month

xxx

Success Rate

10/18 ratings generated profit

Average Return

+6.69%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +6.69% per trade.

3 Months

xxx

Success Rate

8/14 ratings generated profit

Average Return

+5.99%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +5.99% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

13/14 ratings generated profit

Average Return

+45.24%

reiterated a buy rating 15 days ago

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +45.24% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+78.06%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +78.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GH Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, GH has received 31 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. GH average Analyst price target in the past 3 months is 71.06.

Each month's total comprises the sum of three months' worth of ratings.

GH Financial Forecast

GH Earnings Forecast

Next quarter’s earnings estimate for GH is -$0.79 with a range of -$0.86 to -$0.71. The previous quarter’s EPS was -$0.80. GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year GH has Preformed in-line its overall industry.

GH Sales Forecast

Next quarter’s sales forecast for GH is $235.61M with a range of $231.60M to $239.82M. The previous quarter’s sales results were $232.09M. GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year GH has Preformed in-line its overall industry.

GH Stock Forecast FAQ

What is GH’s average 12-month price target, according to analysts?

Based on analyst ratings, Guardant Health’s 12-month average price target is 71.06.

What is GH’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GH, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is GH a Buy, Sell or Hold?

Guardant Health has a consensus rating of Strong Buy which is based on 21 buy ratings, 0 hold ratings and 0 sell ratings.

What is Guardant Health’s price target?

The average price target for Guardant Health is 71.06. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $60.00. The average price target represents -1.51% Decrease from the current price of $72.15.

What do analysts say about Guardant Health?

Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of GH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Guardant Health (GH) Stock Forecast & Price Target

GH Analyst Ratings

GH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Guardant Health

GH Analyst Recommendation Trends

GH Financial Forecast

GH Earnings Forecast

GH Sales Forecast

GH Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts